Preview

Современная ревматология

Расширенный поиск

Современные представления о фармакотерапии псориатического артрита

https://doi.org/10.14412/1996-7012-2015-4-83-91

Полный текст:

Аннотация

Обзор посвящен современным фармакологическим подходам к лечению псориатического артрита (ПсА). Приведены данные о распространенности псориаза и псориатического поражения суставов, нередко являющегося причиной ранней инвалидизации больных. Подходы к оценке эффективности препаратов даны на основании разработанных и используемых критериев, с учетом стандартизованной оценки динамики суставного поражения ревматических заболеваний и, в частности, ПсА. Представлена краткая информация о механизме действия препаратов, приведены результаты клинических исследований, в которых оценивались эффективность и безопасность различных лекарственных средств при ПсА. Обзор охватывает опыт применения нестероидных противовоспалительных препаратов, глюкокортикоидов, синтетических базисных противовоспалительных препаратов (метотрексат, циклоспорин, лефлуномид, сульфасалазин), а также перспективную группу генно-инженерных биологических препаратов. Особое внимание уделено результатам применения ингибиторов фактора некроза опухоли (этанерцепт, инфликсимаб, голимумаб, цертолизумаба пэгол, адалимумаб), ингибиторов интерлейкинов (устекинумаб, бродалумаб) и ингибиторов фосфодиэстеразы 4 (апремиласт).

Об авторах

Г. Г. Тарадин
Донецкий национальный медицинский университет им. М. Горького
Украина
84404, Донецкая область, г. Красный Лиман, ул. Кирова, 27


Н. Т. Ватутин
Донецкий национальный медицинский университет им. М. Горького
Украина
84404, Донецкая область, г. Красный Лиман, ул. Кирова, 27


Д. В. Антоненко
Донецкий национальный медицинский университет им. М. Горького
Украина
84404, Донецкая область, г. Красный Лиман, ул. Кирова, 27


А. С. Смирнова
Донецкий национальный медицинский университет им. М. Горького
Украина
84404, Донецкая область, г. Красный Лиман, ул. Кирова, 27


Литература

1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl. II: ii14-ii17. doi: 10.1136/ard.2004.032482.

2. Мельниченко АБ, Кочергин НГ, Белоусова ТА. Псориатический артрит: клиническая картина, диагностика и терапия. Клиническая дерматология и венерология. 2010;(5):17-24 [Mel'nichenko AB, Kochergin NG, Belousova TA. Psoriatic arthritis: the clinical picture, diagnosis and therapy. Klinicheskaya dermatologiya i venerologiya. 2010;(5):17-24 (In Russ.)].

3. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of psoriasis and psoriatic arthritis in adults. Edinburgh: SIGN; 2010. P. 1-65.

4. Day MS, Nam D, Goodman S, et al. Psoriatic Arthritis. J Am Acad Orthop Sur. 2012;20:28-37. doi: 10.5435/JAAOS-20-01-028.

5. Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther. 2013:7:201-10. doi: 10.2147/DDDT.S32713.

6. Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheumatol. 2009;61(2):233-9. doi: 10.1002/art.24172.

7. Kivelevitch D, Mansouri B, Menter A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics. 2014;8:169-82.

8. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population in the USA. J Am Acad Dermatol. 2005;53(4):573.e1-573.e13. doi: 10.1016/j.jaad.2005.03.046.

9. Reich K, Krü ger K, Mö ssner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040-7. doi: 10.1111/j.1365-2133.2008.09023.x.

10. Mease PJ. Cytokine blockers in psoriatic arthritis. Ann Rheum Dis. 2001;60:iii37-iii40.

11. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39(112):2013-20. doi: 10.1002/art.1780391210.

12. Mease PJ. Measures of psoriatic arthritis. Arthritis Care Res. 2011;63(S11):S64-S85. doi: 10.1002/acr.20577.

13. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl II):ii49-ii54. doi: 10.1136/ard.2004.034165.

14. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48-53. doi: 10.1136/ard.2008.102053.

15. Heuft-Dorenbosch L, Spoorenberg A, van Tubergenetal A. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003;62:127-32. doi: 10.1136/ard.62.2.127.

16. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4-12. doi: 10.1136/annrheumdis-2011-200350.

17. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451-85. doi: 10.1016/j.jaad.2009.03.027.

18. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol. 2010;160:810-20. doi: 10.1111/j.1476-5381.2010.00702.x.

19. Goulabchand R, Mouterde G, Barnetche T, et al. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2014;73:414-9. doi: 10.1136/annrheumdis-2012-202641.

20. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systemic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71:319-26. doi: 10.1136/ard.2011.150995.

21. Sarzi-Puttini P, Santandrea S, Boccassini L, et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol. 2001;19(1 Suppl 22):S17-20.

22. Kivitz AJ, Espinoza LR, Sherrer YR, et al. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin Arthritis Rheum. 2007;37:164-73. doi: 10.1016/j.semarthrit.2007.03.004.

23. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64(Suppl II):ii74-ii77. doi: 10.1136/ard.2004.030783.

24. Mease PJ. Methotrexate in psoriatic arthritis. Bull Hosp Jt Dis. 2013;71 (Suppl 1):S41-5.

25. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology. 2012;51(8):1368-77. doi: 10.1093/rheumatology/kes001.

26. Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71(4):541-8. doi: 10.1136/ard.2011.152223.

27. Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S132-7.

28. Gaies E, Jebabli N, Trabelsi S, et al. Methotrexate side effects: review article. J Drug Metab Toxicol. 2012;3:123-5. doi:10.4172/2157-7609.1000125.

29. Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014; 74:423-41. doi: 10.1007/s40265-014-0191-y.

30. Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol. 1995;22(5):894-8.

31. Karanikolas GN, Koukli EM, Katsalira A. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol. 2011;38(11):2466-74. doi: 10.3899/jrheum.110242.

32. Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf. 1999;20:437-49. doi: 10.2165/00002018-199920050-00004.

33. Huynh DQ, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology. 2014;263:1-9. doi: 10.1093/rheumatology/keu237.

34. Villasenor-Park J, Wheeler D, Grandinetti L. Psoriasis: evolving treatment for a complex disease. Cleve Clin J Med. 2012;79(6):413-23. doi: 10.3949/ccjm. 79a.11133.

35. Behrens F, Finkenwirth C, Pavelka K, et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res. 2013;65(3):464-70. doi: 10.1002/acr.21848.

36. Heiberg MS, Kaufmann C, Rodevand E, et al. The comparative effectiveness of antiTNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis. 2007;66:1038-42. doi: 10.1136/ard.2006.064808.

37. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33(4):712-21.

38. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150-7. doi: 10.1136/ard.2004.032268.

39. Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2006;10(31):1-239. doi: 10.3310/hta10310.

40. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Arthritis Rheum. 2009;60(4):976-86. doi: 10.1002/art.24403.

41. Mease PJ, Fleischmann R, Deodhar АА. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomized placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48-55. doi: 10.1136/annrheumdis-2013-203696.

42. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517-24. doi: 10.1136/annrheumdis-2011-201244.

43. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56(2):476-88. doi: 10.1002/art.22379.

44. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702-9. doi: 10.1136/ard.2008.092767.

45. Spadaro A, Montepaone M, Lubrano E. A novel biological target for the treatment of psoriatic arthritis. Immunotherapy. 2014;6(5):515-8. doi: 10.2217/imt.14.39.

46. Krueger G, Langley R, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580-92. doi: 10.1056/NEJMoa062382.

47. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebocontrolled, crossover trial. Lancet. 2009;373(9664):633-40. doi: 10.1016/S0140-6736(09)60140-9.

48. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, doubleblind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2.

49. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481-511. doi: 10.1146/annurev.biochem.76.060305.150444.

50. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol. 2011;204:391-414. doi: 10.1007/978-3-642-17969-3_17.

51. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebocontrolled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014 Jun;73(6):1020-6. doi: 10.1136/annrheumdis-2013-205056. Epub 2014 Mar 4.

52. Schafer PH, Partona A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26:2016-29. doi: 10.1016/j.cellsig.2014.05.014.

53. Cauli A, Porru G, Piga M, et al. Clinical potential of apremilast in the treatment of psoriatic arthritis. Immunotargets Ther. 2014:3:91-6. doi: 10.2147/ITT.S40199.

54. Mease PJ, Genovese MС, Greenwald MW, et al. Brodalumab, an antiIL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370:2295-306. doi: 10.1056/NEJMoa1315231.


Для цитирования:


Тарадин Г.Г., Ватутин Н.Т., Антоненко Д.В., Смирнова А.С. Современные представления о фармакотерапии псориатического артрита. Современная ревматология. 2015;9(4):83-91. https://doi.org/10.14412/1996-7012-2015-4-83-91

For citation:


Taradin G.G., Vatutin N.T., Antonenko D.V., Smirnova A.S. Current views on the pharmacotherapy of psoriatic arthritis. Modern Rheumatology Journal. 2015;9(4):83-91. (In Russ.) https://doi.org/10.14412/1996-7012-2015-4-83-91

Просмотров: 467


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)